Unique ID issued by UMIN | UMIN000038620 |
---|---|
Receipt number | R000044017 |
Scientific Title | A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patients |
Date of disclosure of the study information | 2019/12/01 |
Last modified on | 2023/04/10 09:58:29 |
A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patients
A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patients
A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patients
A study of the contributions of neurotransmitter systems and abnormal protein pathologies in the brain to the symptoms of FTLD-ALS spectrum patients
Japan |
FTLD-ALS spectrum
Neurology |
Others
NO
This study aims to quantify the density of metabotropic glutamate subtype 5 receptor and accumulated amyloid-beta and tau proteins, and to assess the association among neurotransmission, brain abnormally accumulated proteins, and clinical features in FTLS-ALS spectrum patients.
Efficacy
The associations between neurotransmitter systems evaluated by PET with (E)-[11C]ABP688 and MRI/MRS, and clinical symptoms.
The associations between neurotransmitter systems evaluated by PET with (E)-[11C]ABP688 and MRI/MRS, and abnormally aggregated protein measured by PET with [18F]PM-PBB3 and [11C]PiB.
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
2
Diagnosis
Other |
PET/MRI/psychological batteries/neurological examinations
PET/MRI/psychological batteries/neurological examinations
20 | years-old | <= |
Not applicable |
Male and Female
1) FTLD-ALS spectrum patients
1. 20 years of age or older at the time of obtaining consent
2. Subjects who can be accompanied by a legal guardian on the day of study participation
3. Subjects met with clinical diagnostic criteria of ALS or FTLD
2) Healthy volunteers
1. 20 years of age or older at the time of obtaining consent
2. Subjects with ability to make informed consent
1) FTLD-ALS spectrum patients
1. Subjects with organic brain complications/disorders
2. Subjects with substance-related disorders
3. Subjects with severe physical complications/disorders or a history of such conditions
4. Subjects with claustrophobia
5. Pregnant, possibly pregnant or lactating women
6. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study (at National Institutes for Quantum and Radiological Science and Technology)
7. Subjects with metallic medical device in the body (at Nagoya university)
8. Subjects with tattoo (at Nagoya university)
9. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study
2) Healthy volunteers
1. Subjects with organic brain complications/disorders
2. Subjects with substance-related disorders
3. Subjects with severe physical complications/disorders or a history of such conditions
4. Subjects with metallic medical device in the body
5. Subjects with tattoo
6. Subjects with claustrophobia
7. Pregnant, possibly pregnant or lactating women
8. From the standpoint of radiation exposure from a nuclear medicine scan, subjects who have participated in other nuclear medicine scans as healthy volunteers in the 6 months prior to the start of this study (at National Institutes for Quantum and Radiological Science and Technology)
9. Subjects who are considered to be inappropriate for participation by doctors with responsibilities in this study
50
1st name | Kiwamu |
Middle name | |
Last name | Matsuoka |
National Institutes for Quantum and Radiological Science and Technology
Department of Functional Brain Imaging Research, National Institute of Radiological Sciences
263-0024
4-9-1 Anagawa, Inage-ku, Chiba
+81-43-206-3251
matsuoka.kiwamui@qst.go.jp
1st name | Kazuko |
Middle name | |
Last name | Suzuki |
National Institutes for Quantum and Radiological Science and Technology
Clinical Research Support Section, National Institute of Radiological Sciences
263-0024
4-9-1 Anagawa, Inage-ku, Chiba
+81-43-206-3251
suzuki.kazuko@qst.go.jp
National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology
National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology
Other
Center for Brain and Mind Research Promotion, Nagoya University Graduate School of Medicine
Japan Agency for Medical Research and Development
Certified Review Board
4-9-1 Anagawa, Inage-ku, Chiba
+81-43-206-4709
helsinki@qst.go.jp
NO
2019 | Year | 12 | Month | 01 | Day |
Unpublished
Completed
2019 | Year | 10 | Month | 26 | Day |
2019 | Year | 10 | Month | 25 | Day |
2019 | Year | 12 | Month | 09 | Day |
2022 | Year | 03 | Month | 31 | Day |
2019 | Year | 11 | Month | 19 | Day |
2023 | Year | 04 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044017
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |